Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SAT1 | P21673 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 2/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23491205 | 1.00 | GNAI3 (0.36) | GNAI3GNAO1GNAI1FDPSLMNA | |
| SCHEMBL19880464 | 0.88 | GNAI3 (0.41) | GNAI3GNAO1GNAI1FDPSLMNA | |
| SCHEMBL19779958 | 0.88 | GNAI3 (0.49) | GNAI3GNAO1GNAI1FDPSLMNA | |
| SCHEMBL20621253 | 0.85 | GNAI3 (0.40) | GNAI3GNAO1GNAI1FDPSLMNA | |
| SCHEMBL19880466 | 0.84 | SPHK1 (0.35) | GNAI3GNAO1GNAI1FDPSADH1B | |
| SCHEMBL19779757 | 0.84 | GNAI3 (0.42) | GNAI3GNAO1GNAI1FDPSLMNA | |
| SCHEMBL19779740 | 0.84 | GNAI3 (0.40) | GNAI3GNAO1GNAI1FDPSLMNA | |
| SCHEMBL21883530 | 0.82 | GNAI3 (0.37) | GNAI3GNAO1GNAI1FDPSZDHHC7 | |
| SCHEMBL21884007 | 0.81 | ADH1B (0.33) | FDPSADH1BADH1CADH1AADH4 | |
| SCHEMBL19780177 | 0.77 | OPRM1 (0.35) | FDPSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | GNAI3 572/4885GNAO1 897/4885GNAI1 596/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | GNAI3 572/4885GNAO1 897/4885GNAI1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.